Ivermectin does show antiviral activity in laboratory settings against a range of viruses, but the concentrations required to achieve that effect are far higher than what the human body reaches with standard or even elevated doses. This gap between what works in a petri dish and what works in a living person is the central issue in the ivermectin antiviral debate.
How Ivermectin Interferes With Viruses
Ivermectin was developed as an antiparasitic drug and has been used for decades to treat conditions caused by parasitic worms, such as river blindness and intestinal strongyloidiasis. Its potential antiviral activity was identified through a different mechanism entirely. In cell cultures, ivermectin blocks a specific transport system that many viruses rely on to shuttle their proteins into the nucleus of a host cell. This system uses a pair of carrier proteins that act like a shuttle bus, ferrying viral cargo through the nuclear membrane. Ivermectin appears to bind to one of these carriers and prevent it from recognizing the viral proteins it would normally transport. Without access to the nucleus, certain viruses can’t hijack the cell’s machinery to replicate efficiently.
This transport system is used by a wide range of both DNA and RNA viruses, which is why ivermectin has shown broad activity in lab experiments rather than targeting just one virus family.
Viruses Inhibited in Lab Settings
The list of viruses ivermectin has suppressed in cell cultures is genuinely broad. Among RNA viruses, it has shown activity against dengue, Zika, West Nile, yellow fever, chikungunya, Sindbis, and SARS-CoV-2. Among DNA viruses, it reduced levels of pseudorabies virus and porcine circovirus 2 in animal studies. In one experiment with Usutu virus (a flavivirus related to West Nile), the concentration needed to cut viral replication by half ranged from roughly 0.5 to 2 micromolar depending on the cell type, with a selectivity index (the margin between the effective dose and the toxic dose) between about 6 and 13.
These are legitimate findings. The problem isn’t that the lab data is fabricated or meaningless. It’s that “works in a dish” and “works in a person” are separated by a massive pharmacological gap.
The Concentration Problem
This is the crux of the issue. To inhibit SARS-CoV-2 in cell culture, researchers needed a concentration of about 2.5 micromolar, which translates to roughly 2,190 nanograms per milliliter of fluid. When a person takes the standard FDA-approved oral dose of 200 micrograms per kilogram of body weight, their peak blood concentration falls well below that threshold. Even at the highest dose tested in published pharmacokinetic studies (approximately 1,700 micrograms per kilogram, or about 8.5 times the standard dose), the peak plasma concentration reached only 0.28 micromolar. That’s roughly one-ninth of the concentration needed to achieve a 50% reduction in viral replication in a lab dish.
In practical terms, you cannot swallow enough ivermectin to reach antiviral concentrations in your blood without risking serious toxicity. This is the reason most pharmacologists have been skeptical about oral ivermectin as an antiviral, regardless of how promising the cell culture data looks.
Could Inhaled Delivery Change the Math?
One approach researchers have explored is delivering ivermectin directly to the lungs through inhalation, bypassing the bloodstream entirely. In a mouse study, inhaled ivermectin reached lung tissue concentrations roughly 80 to 115 times higher than corresponding plasma levels. At a dose of about 3 milligrams per kilogram, lung tissue peaked at around 96 micrograms per gram, while plasma peaked at only 0.84 micrograms per milliliter. The drug also avoided the heavy protein binding that limits its effectiveness when taken orally, and it stayed above potentially antiviral concentrations in lung tissue for at least 24 hours.
This is an interesting proof of concept, but it remains in early animal research. No inhaled ivermectin formulation has been approved for use in humans, and the jump from mouse lungs to human lungs involves significant unknowns about safety, dosing, and tissue distribution.
What Human Trials Have Shown
Several clinical trials have tested ivermectin in people with viral infections. A Phase II/III randomized, placebo-controlled trial evaluated ivermectin in children and adults with dengue fever, comparing two-day and three-day courses against placebo. The primary goal was to see whether ivermectin could speed up clearance of the virus from the bloodstream. That trial has not posted results.
The largest body of human trial data involves COVID-19. The World Health Organization reviewed pooled data from 16 randomized controlled trials enrolling a total of 2,407 patients, both hospitalized and outpatient. The conclusion: evidence on whether ivermectin reduces death, need for mechanical ventilation, hospital admission, or time to recovery was of “very low certainty” due to small trial sizes and methodological limitations. WHO recommended ivermectin be used for COVID-19 only within clinical trials.
A large U.S. trial published in JAMA tested a higher dose of 600 micrograms per kilogram (three times the standard antiparasitic dose) given daily for six days in outpatients with COVID-19. That dose was generally well tolerated, with some self-resolving visual disturbances, but it did not meaningfully shorten time to recovery compared to placebo.
Why Lab Results Don’t Always Translate
Ivermectin is not unique in this pattern. Many drugs kill viruses effectively in cell cultures but fail in the body. Cells in a dish sit in a uniform bath of drug at a controlled concentration. In a living person, the drug has to survive digestion, get absorbed into the blood, avoid being bound up by proteins (which makes it inactive), distribute into the right tissues at the right concentration, and do all of this without causing harm. Ivermectin is highly protein-bound in blood plasma, meaning most of the circulating drug is locked up and unavailable to interact with viruses.
The selectivity index matters here too. A selectivity index of 6 to 13 (as seen in Usutu virus experiments) means the toxic concentration is only 6 to 13 times higher than the effective concentration. That’s a narrow margin. For comparison, drugs that make it through development typically have much wider safety margins.
Current Approved Uses
Ivermectin tablets are FDA-approved for two parasitic conditions: intestinal strongyloidiasis and onchocerciasis (river blindness). Topical formulations are approved for head lice and rosacea. It is not approved by the FDA, WHO, or any major regulatory body as an antiviral treatment for any virus. Its antiviral properties remain a laboratory observation that has not successfully crossed into clinical practice.